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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S292of both cytokines is effective early in the process of cartilage damage. In
this study it is investigated whether a single intra-articular injection of
IL-4 plus IL-10 immediately after a joint bleed limits cartilage damage in
an in vivo haemophilia mouse model.
Methods: Factor VIII knockout mice were punctured once with a needle
below the patella to induce a joint bleed. Subsequently IL-4 plus IL-10
(n¼24) or vehicle (n¼24) was injected intra-articularly once. After 35
days, the knee joints were examined for cartilage damage by macro-
scopic and microscopic evaluation using the OARSI histopathology
score speciﬁc for mice for cartilage degeneration and the Valentino
score for synovial inﬂammation. The left knee joint in both groups
served as an unaffected control.
Results: Induction of a joint bleed led to a signiﬁcant increase in
macroscopic remains of a joint bleed and to an increase in joint
diameter in both groups compared to the unaffected joints (all p<0.05
compared to control). Although not statistically signiﬁcant, the IL-4
plus IL-10 injected joints tended to present less remains of a joint
bleed compared to the vehicle injected joints (46% versus 58%;
p¼0.386). Moreover, the diameter of the joints injected with IL-4 plus
IL-10 tended to be smaller than that of the vehicle injected joints
(2.630.16mm vs 2.910.29mm; p¼0.174). After a joint bleed, the
OARSI score as well as the Valentino score increased compared to the
unaffected joints. Intra-articular injection of IL-4 and IL-10 amelio-
rated cartilage degeneration caused by the joint bleed (mean change
in OARSI score in experimental joint compared to control joint for
vehicle injection 0.91.2 (p¼0.010) and for IL-4 plus IL-10 injection
0.51.8 (p¼0.216)). No effect on inﬂammationwas observed at 35 days
after the joint bleed for IL-4 plus IL-10 compared to vehicle (mean
Valentino score after IL-4 plus IL-10 injection 3.61.8 and for vehicle
injection 2.92.0 (p¼0.220)).
Conclusion: A single intra-articular injection of IL-4 plus IL-10 directly
after a single joint bleed limits cartilage degeneration, but not synovial
inﬂammation. Improved bioavailability of both cytokines might
improve the protective ability of both cytokines in development of
cartilage degeneration, and probably also inﬂammation.
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DIFFERENT CHANGES IN THE BIOMARKER CTX-II FOLLOWING
INTRA-ARTICULAR INJECTION OF HIGH MOLECULAR WEIGHT
HYALURONIC ACID AND ORAL NON-STEROIDAL ANTI-
INFLAMMATORY DRUGS FOR PATIENTS WITH KNEE
OSTEOARTHRITIS: A MULTI-CENTER RANDOMIZED CONTROLLED
STUDY
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Purpose: Intra-articular injections of hyaluronic acid (IA-HA) and oral
non-steroidal anti-inﬂammatory drugs (NSAIDs) are both recom-
mended by OARSI for the management of knee OA. However, their
molecular effects on the pathophysiology of knee OA remain unclear. A
C-terminal telopeptides of type II collagen (CTX-II) is biomarker
discovered as a marker of type II collagen degradation. Recently, CTX-II
has found to originate primarily from the interface between sub-
chondral bone and articular cartilage which is a site of potential
remodeling in OA. The regulation of CTX-II release is more reﬂective of
bone rather than cartilage metabolism. The aim of this study, the sub-
analysis of the multicenter RCT [the result of the primary endpoint
(OARSI 2012)] was to compare the changes of CTX-II in response to IA-
HA to those in response to NSAID treatment for knee OA.
Methods: A total of 200 patients with knee OA (K/L 1 to 3) were
registered from 20 hospitals and randomized to IA-HA (High molecular
weight 2,700 kDa HA) or NSAID (loxoprofen sodium). For patients
treated with NSAID, they used NSAID 3 tablets (180 mg)/day for 5
weeks. For patients treated with IA-HA, IA-HAwas conducted 5 times atoneweek intervals. The fasted second void urine samples collected from
all patients were stored at -80Co until analysis. uCTX-II levels were
corrected for urine creatinine concentration. The CTX-II data were
analyzed by the per protocol set (PPS).
Results: Half (100) of the patients were randomly allocated into the
NSAID group, and the other half allocated into the IA-HA group. After
the 5 week treatment period, 68 of 100 of the patients in the IA-HA
group and 58 of 100 of those in the NSAID group were eligible for CTX-II
analysis. At baseline, no signiﬁcant differences of baseline characteris-
tics were observed between IA-HA and NSAID groups. The Japanese
Knee Osteoarthritis Measure (JKOM) score of the patients in both the IA-
HA (-37.4%) and NSAID (-35.3%) groups were signiﬁcantly reduced
following treatment (p<0.001). The difference in the percent changes of
the JKOM score between the two intervention arms was -2.1% (90%CI;
-10.9 to 6.2%), demonstrating the non-inferiority of IA-HA to the NSAID
for the reduction in the clinical symptoms. uCTX-II levels were signiﬁ-
cantly reduced by the NSAID treatment. In contrast, uCTX-II levels were
signiﬁcantly increased by the IA-HA treatment. The percent changes of
uCTX-II by IA-HA treatment (11.6%) were signiﬁcantly different than
those of that by NSAID treatment (-9.0%) (p<0.0001). When the
patients were analyzed based on the radiographic severity of knee OA,
the differences of uCTX-II responses between the NSAID and IA-HA
were again observed.
Conclusions: We observed in this RCT that IA-HA treatment increased
uCTX-II levels, while oral NSAID reduced uCTX-II levels, while both
treatments improved symptoms of pts. with knee OA. The differences in
biomarker response suggest different modes of action, each with
a beneﬁcial effect on symptom: one being stimulatory of cartilage/bone
interface extracellular matrix type II collagen turnover (IA-HA) and the
other reducing such turnover.
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PHARMACOKINETICS OF A THERMALLY RESPONSIVE CURCUMIN
CONJUGATE FOR LOCAL ANTAGONISM OF NEUROINFLAMMATION
IN DISC HERNIATION
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Purpose: Tumor necrosis factor alpha (TNFa) is believed to be a key
mediator of inﬂammatory events associated with herniated interver-
tebral disc (IVD). Local delivery of TNF antagonists via epidural injec-
tions to treat pain or dysfunction associated with herniated IVD has
been studied in the clinic with some success. We hypothesize that
sustained release of injectable depots containing cytokine antagonists
can be a safer, cost-effective treatment for relieving pain associated
with IVD herniation. We have designed novel drug conjugates
comprised of elastin-like polypeptides (ELP) and a small anti-inﬂam-
matory compound, curcumin, which has an excellent safety proﬁle in
clinical trials. ELPs are biocompatible, biodegradable polymers that are
soluble below a transition temperature (Tt,) and form micron-sized
depots above Tt. Here, we report on the pharmacokinetics and clearance
rates of injectable, ELP-curcumin conjugate ‘depots’ delivered to the
perineural space in mice.
Methods: A novel derivative of curcumin, monofunctional curcumin
carbamate (MCC, Fig 1), was chemically coupled to glutamate-con-
taining ELPs (Fig 2). Drug-carrier ratio, conjugate purity, Tt, and
hydrodynamic radius (Rh) were quantiﬁed with UV-Vis, RP-HPLC, and
dynamic light scattering. In vitro bioactivity of conjugates against TNFa-
induced proliferation was quantiﬁed with L929 cells as previously
described. For in vivo studies, the right sciatic nerve of C57BL/6 female
mice (n¼3 per group, 12 weeks old) was surgically exposed, and cur-
cumin or ELP-MCC (25ml, 150nmol) was delivered to the perineural
space. Blood was collected at times from 0.5 to 168 hours and tissues
were harvested at varying sacriﬁce times from 2 to 168 hours. Plasma
and solubilized tissue was analyzed for curcumin presence via
ﬂuorescence.
Results: ELP-MCC conjugates were synthesized and characterized to
have mean drug-carrier ratios of 5.7 to 1 (MW¼37.8kDa), >90% purity,
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depots. ELP-MCC retained bioactivity against TNFa in vitro with an IC50
2-fold higher than curcumin (24.1mM and 13.5mM, respectively, n¼4).
Following perineural delivery to the sciatic nerve, ELP-MCC displayed
decreased plasma exposure levels compared to curcumin and evidence
of sustained drug release over 96 hrs (Fig 3). Curcumin was completely
cleared from the delivery site after 48 hrs, while low levels of ELP-MCC
remained at the delivery site 96 hrs after delivery.
Conclusions: ELP-MCC conjugates retain activity against TNFa and
provided for sustained release of drug in vivo. These ﬁndings suggest
that ELP may be a suitable carrier for local antagonism of inﬂammation
in back pain. The development of sustained-release drug delivery
systems, such as ELP-MCC, has substantial translational potential for
treating chronic pain and inﬂammation for localized pathologies.
Acknowledgements: This work was funded by the NIH (R01AR047442,
P01AR050245).Ă
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ASSOCIATIONS BETWEEN STATIN USE AND CHANGES IN PAIN,
FUNCTION AND STRUCTURAL PROGRESSION: A LONGITUDINAL
STUDY OF PERSONS WITH KNEE OSTEOARTHRITIS
D.L. Riddle, G. Moxley, L. Dumenci. Virginia Commonwealth Univ.,
Richmond, VA, USA
Purpose: Recently published research suggests that statins may have
beneﬁcial structural effects in persons with knee osteoarthritis. The
potential effects of statins on patient-reported knee pain and function
have not been examined. We studied a large prospective community-
based cohort of persons with knee osteoarthritis to determine if statin
usage was associated with changes in knee structure, pain and function
trajectories over a 4-year period.
Methods: Data were obtained from a subset of 2,207 persons in the
Osteoarthritis Initiative with radiographically suspected or conﬁrmed
knee osteoarthritis. The changes in WOMAC Pain and Physical Function
scores, pain intensity and Kellgren-Lawrence radiographic grade over
four years were examined. Data from persons were coded based on
whether they were incident users of statins over the 4-year period.
Statin use duration data also were collected. Outcome trajectories and
probability of statin use were examined over the 4-year study period
using parallel processing growth curve modeling. The analysis adjusted
for potential confounders and determined if statin use predicted
outcome trajectories.
Results: Statin users accounted for 6.7% of the sample in year 1 and
16.4% in year 4. Extent of statin use was not associated with improve-
ments in knee pain, function or structural progression trajectories. The
only signiﬁcant ﬁnding indicated that increased duration of statin use
was associated with worsening in WOMAC Physical Function scores
over the study period (beta¼ 0.161, p¼ 0.005). The Figure illustrates the
full structural equation model for WOMAC Physical Function scores and
statin use over the study period.
Conclusions: Statin use was not associated with improvements in knee
pain, function, or structural progression over the 4-year study period.Ă
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IMPROVEMENT OF SYMPTOMS IN THE GENERALIZED
OSTEOARTHRITIS USE OF ZOLEDRONIC ACID ZOLA STUDY
L.A. gutierrez, Sr.. Hosp. Univ.rio de Caracas, Caracas, Bolivarian Republic
Of Venezuela
Purpose: In the past it was thought that osteoarthritis (OA) was
a disease of wear, current evidence indicates that the OA is an
inﬂammatory disease signs given by the presence of synovial hyper-
plasia, increased angiogenesis, increased expression of IL-1, TNF, COX-
2 and matrix metalloproteinases (MMP). The activation of chon-
drocytes by mechanical stress, inﬂammatory cytokines, fragments of
collagen and ﬁbronectin, leading to the production of IL-1, TNF-alpha
and PGE2 nitric oxide, which in turn determine the reduction of
proteoglycan synthesis , activation of MMP, peroxynitrate, JNK acti-
vation and apoptosis of chondrocytes which ultimately leads to
cartilage destruction. The cartilage damage leads to increased trans-
mission of forces to the underlying bone due to the decreased elas-
ticity of cartilage, bone microfractures and this produces increased
bone turnover. All these changes occur in the subchondral bone, we
know the holding capacity of bisphosphonates on bone turnover in
2005 presented the results of the BRISK study (Risedronate in OA),
however the dose used was 15mg / d with increased adverse effects
and poor adherence to medication.
Methods: The type of study was a prospective, uncontrolled with
quarterly assessments following the application of zoledronic acid
5mg/100cc semester. The selection of patients was conducted during
October 2009 to December 2011, including 85 patients (n ¼ 85), with
over 50 years and diagnosed with osteoarthritis in three or more joint
groups (distal and proximal interphalangeal, ﬁrst carpometacarpal ,
axial skeleton, hips, knees and metatarsophalangeal). We excluded
patients who were receiving bisphosphonates for 6 months before
recruitment as well as patients with a history of fractures, severe
osteoporosis and joint replacement. We used the WOMAC index that
measures 3
ITEM: Pain, stiffness and physical function, in addition we applied the
visual analog scale (VAS) and asked about the use of NSAIDs and / or
pain in the last days of applying 5-3-2 the questionnaire. We measured
serum CTX-II every 3 months.
Results: Of all patients who entered the study (n ¼ 85): 73.3% (n ¼ 74)
were female and 26.6% (n ¼ 9) male, with a mean (M  SD) of 61.88 
7.33 years, BMI 29.2  58.5 baseline WOMAC Kg/mt2 2.3, 59.1  2.0 3m
WOMAC, WOMAC 6m 47  1.6; measurement baseline VAS 7.5  0.2;
VAS3m 4.2  0.5; VAS6m 2.5  1.2; baseline CTx-II 0,735  0,036 ng /
mol; CTx-II 3m 0.548  0.014 ng / mol; CTx-II 6m 0.233  0.002 ng /
mol.
Conclusions: In this study we observed a substantial improvement
with the use of bisphosphonates in cross section at 6 months was
achieved in addition to reducing the taking of NSAIDs and / or pain after
implementation, the sustained reduction in CTx-Biomarker II remained
even last 3 months of the ﬁrst application. Because the court date is not
radiological control measures were shown to be effective from a struc-
tural standpoint
